嵌合抗原受体T细胞疗法治疗B细胞血液系统恶性肿瘤：关键临床试验数据更新
Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data.
作者信息
Roex Gils, Feys Tom, Beguin Yves, Kerre Tessa, Poiré Xavier, Lewalle Philippe, Vandenberghe Peter, Bron Dominique, Anguille Sébastien
机构信息
Tumor Immunology Group, Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, 2650 Edegem, Belgium.
Ariez International BV, 9000 Ghent, Belgium.
出版信息
Pharmaceutics. 2020 Feb 24;12(2):194. doi: 10.3390/pharmaceutics12020194.
Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The treatment is currently also being studied in other B-cell neoplasms, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). CD19 and B-cell maturation antigen (BCMA) have been the most popular target antigens for CAR-T-cell immunotherapy of these malignancies. This review will discuss the efficacy and toxicity data from the pivotal clinical studies of CD19- and BCMA-targeted CAR-T-cell therapies in relapsed/refractory B-cell malignancies (NHL, ALL, CLL) and MM, respectively.
嵌合抗原受体（CAR）-T细胞疗法是过继性细胞疗法的一种创新形式，它彻底改变了某些血液系统恶性肿瘤的治疗方式，包括B细胞非霍奇金淋巴瘤（NHL）和B细胞急性淋巴细胞白血病（ALL）。目前该疗法也正在其他B细胞肿瘤中进行研究，包括多发性骨髓瘤（MM）和慢性淋巴细胞白血病（CLL）。CD19和B细胞成熟抗原（BCMA）一直是这些恶性肿瘤CAR-T细胞免疫疗法最常用的靶抗原。本综述将分别讨论针对复发/难治性B细胞恶性肿瘤（NHL、ALL、CLL）和MM的CD19靶向和BCMA靶向CAR-T细胞疗法关键临床研究的疗效和毒性数据。
Zotero 插件